Draft Genetic Testing Policies - Blue Advantage
Blue Cross and Blue Shield of Alabama partners with Carelon Medical Benefits Management, an independent company, to administer genetic testing solutions for our customers.
Carelon is our business associate and has agreed to follow our privacy and security policies regarding the confidentiality and protection of your personal health information.
Draft Genetic Testing Policies
As part of the Carelon guideline annual review process, the below updates focus on advancing efforts to drive clinically appropriate, safe and affordable healthcare services.
Effective for dates of service on and after October 20, 2024, the following updates apply to Carelon's Genetic Testing Clinical Appropriateness Guidelines.
Effective for dates of service on and after November 17, 2024, the changes in the document below will apply to the Carelon Medical Benefits Management Genetic Testing Clinical Appropriateness Guidelines.
To continue to the Carelon website to view genetic testing policies, click "Accept" below.
Comment on Draft Policies
To ensure that the development of medical policies occurs through an open, collaborative process, we welcome comments about medical policies that are in the draft stage.
Participating providers are invited to submit scientific, evidence-based information, professional consensus opinions and other information supported by medical literature relevant to these draft policies for consideration.
Comments are accepted for 45 days from the posting date listed on the draft policy.
Make sure your voice is heard by providing feedback directly to us:
- Complete our online medical policy feedback form, or
- Send comments by mail or fax to:
Blue Cross and Blue Shield of Alabama
Attn: Health Management - Medical Policy
P.O. Box 995
Birmingham, AL 35298-0001
Fax: 205-220-0878